InVitria Reveals Technology to Optimize Hybridoma Production Performance
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Recent studies using both classical media and the leading commercial serum-free hybridoma media formulations proved that InVitria’s cell culture supplements optimized cell growth and productivity of hybridoma cells. Further, the studies revealed that Cellastim supports cell adaptation and survival in chemically-defined media.
Additional findings from the study showed that Cellastim improved the cell growth and productivity in long-term culture. In a 25-day period, cell doublings in Cellastim-supplemented media were twice that of media without Cellastim. Also, antibody production was 65% higher in the commercial media with Cellastim while cells supplemented with Cellastim grew to higher density than those in unsupplemented media.
“This research incorporated classical media as well as several leading commercial media available on the market,” said Dr. Steve Pettit, the project’s lead researcher. “We achieved optimal cell density and quicker doubling times as well as better cell productivity when Cellastim was added to these media. We also reported that Lacromin improves hybridoma cell culture performance.”
Lacromin increased cell density in supplemented media nearly double compared to that of media without Lacromin supplementation. A significant increase in antibody production was recognized in all Lacromin-treated media, exceeding the level achieved with 5% fetal bovine serum (FBS).
“This research supports what customers have been reporting from their use of Cellastim and Lacromin for hybridoma cell culture,” said InVitria President and CEO Scott Deeter. “Cellastim has been shown to not only optimize hybridoma performance, but also outperform other sources of native and recombinant albumin.”
Additional findings from the study showed that Cellastim improved the cell growth and productivity in long-term culture. In a 25-day period, cell doublings in Cellastim-supplemented media were twice that of media without Cellastim. Also, antibody production was 65% higher in the commercial media with Cellastim while cells supplemented with Cellastim grew to higher density than those in unsupplemented media.
“This research incorporated classical media as well as several leading commercial media available on the market,” said Dr. Steve Pettit, the project’s lead researcher. “We achieved optimal cell density and quicker doubling times as well as better cell productivity when Cellastim was added to these media. We also reported that Lacromin improves hybridoma cell culture performance.”
Lacromin increased cell density in supplemented media nearly double compared to that of media without Lacromin supplementation. A significant increase in antibody production was recognized in all Lacromin-treated media, exceeding the level achieved with 5% fetal bovine serum (FBS).
“This research supports what customers have been reporting from their use of Cellastim and Lacromin for hybridoma cell culture,” said InVitria President and CEO Scott Deeter. “Cellastim has been shown to not only optimize hybridoma performance, but also outperform other sources of native and recombinant albumin.”
